 |
市場調查報告書
商品編碼
1649410
基因生物標記市場 - 預測 2025 年至 2030 年Genomic Biomarkers Market - Forecasts from 2025 to 2030 |
||||||
價格
簡介目錄
基因生物標記市場預計將從 2025 年的 226.31 億美元成長到 2030 年的 361.27 億美元，預測期內的複合年成長率為 9.81%。
基因生物標記是 DNA 或 RNA 的可測量特徵，可指示生物過程、疾病機製或治療反應。這些生物標記提供了了解基因表現量、功能和調控的能力。癌症、心血管疾病和神經系統疾病等慢性疾病的發生率不斷上升，推動了對基因生物標記的需求。此外，政府對醫療保健的資助增加也刺激了該領域的研究和發展。各家公司的創新，尤其是融入人工智慧的創新，正在擴大基因生物標記的應用。此外，人們越來越意識到早期發現疾病的重要性，這也極大地促進了基因生物標記市場的成長：
- 癌症發生率上升：全球癌症發生率的快速增加是基因生物標記診斷的主要驅動力。例如，美國衛生統計中心估計，2023年，美國將有1,958,310例新發癌症病例和609,820例癌症相關死亡病例。
- 最新進展：2023 年 6 月，Invivoscribe 與 Complete Genomics 合作，利用次世代定序平台開發和銷售生物標記測試。這些測試旨在改善可測量殘留疾病（MRD）的領先篩檢和監測，代表了腫瘤學的重要進步。
市場細分：基因生物標記市場按北美、南美、歐洲、中東和非洲、亞太地區進行細分：
- 亞太地區的成長：中國、日本、印度和韓國等主要國家對該地區做出了重大貢獻。根據印度醫學研究理事會的數據，僅在印度，預計 2022 年將有 1,461,427 例新發癌症病例，到 2025 年預計將有 2,980 萬例新發癌症病例。這種急劇的成長刺激了基因生物標記的採用。
- 北美的主導地位：由於 MEDiC Life Sciences 和 Illumina Inc. 等行業領先企業以及該地區正在進行的研究努力，北美預計將佔據基因生物標記市場的很大佔有率。
總體而言，隨著慢性病盛行率的上升和個人化醫療技術的進步，基因生物標記市場預計將實現顯著成長。
為什麼要購買這份報告？
- 深刻分析：獲得深入的市場洞察，涵蓋主要地區和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
- 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
- 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
- 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
- 適合廣泛用戶：對於新興企業、科學研究機構、顧問公司、中小企業和大型企業來說都是有益且具成本效益的。
它有什麼用途？
產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響
研究範圍
- 2022 年至 2030 年的歷史資料與預測
- 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
- 競爭定位、策略和市場佔有率分析
- 細分和區域分析，包括收益成長和預測國家
- 公司概況（包括主要趨勢）
基因生物標記市場細分如下：
按類型
- 預測性生物標記
- 預後生物標記
按適應症
- 腫瘤學
- 心血管疾病
- 神經系統疾病
- 腎臟疾病
- 其他
按最終用途
- 醫院
- 診斷中心
- 其他
按地區
- 北美洲
- 美國
- 加拿大
- 墨西哥
- 南美洲
- 巴西
- 阿根廷
- 其他
- 歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 其他
- 中東和非洲
- 沙烏地阿拉伯
- UAE
- 其他
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 台灣
- 泰國
- 印尼
- 其他
目錄
第 1 章 簡介
- 市場概況
- 市場定義
- 研究範圍
- 市場區隔
- 貨幣
- 先決條件
- 基準年和預測年時間表
- 相關人員的主要利益
第2章調查方法
- 研究設計
- 研究過程
- 資料檢驗
第3章執行摘要
- 主要發現
- 分析師觀點
第4章 市場動態
- 市場促進因素
- 市場限制
- 波特五力分析
- 產業價值鏈分析
第 5 章基因生物標記市場（按類型）
- 介紹
- 預測性生物標記
- 預後生物標記
第 6 章基因生物標記市場（按適應症）
- 介紹
- 腫瘤學
- 心血管疾病
- 神經系統疾病
- 腎臟疾病
- 其他
第 7 章基因生物標記市場（依最終用途）
- 介紹
- 醫院
- 診斷中心
- 其他
第 8 章基因生物標記市場（按地區）
- 世界概況
- 北美洲
- 美國
- 加拿大
- 墨西哥
- 南美洲
- 巴西
- 阿根廷
- 其他
- 歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 其他
- 中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 其他
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 台灣
- 泰國
- 印尼
- 其他
第9章競爭格局及分析
- 主要企業和策略分析
- 新興企業和市場盈利
- 合併、收購、協議和合作
- 競爭儀錶板
第10章 公司簡介
- Almac Group
- Bio-Rad Laboratories Inc.
- Eurofins Scientific
- Myriad Genetics Inc
- QIAGEN
- Thermo Fisher Scientific Inc
- Illumina, Inc.
- REVEAL GENOMICS, SL
- Guardant Health
- Complete Genomics Incorporated
簡介目錄
Product Code: KSI061617234
The genomic biomarkers market is projected to grow at a CAGR of 9.81% over the forecast period, increasing from US$22.631 billion in 2025 to US$36.127 billion by 2030.
Genomic biomarkers refer to measurable traits in DNA or RNA that indicate biological processes, disease mechanisms, and responses to treatments. These biomarkers provide insights into gene expression levels, functionality, and regulation. The increasing prevalence of chronic diseases like cancer, cardiovascular issues, and neurological disorders has heightened the demand for genomic biomarkers. Additionally, greater government funding in healthcare has spurred research and development in this field. Innovations from various companies, particularly those integrating artificial intelligence, are broadening the applications of genomic biomarkers. Moreover, the rising awareness of the importance of early disease detection significantly contributes to market growth.Key Drivers of the Genomic Biomarkers Market:
- Rising Cancer Incidence: The global surge in cancer cases is a major driver for genomic biomarker diagnostics. For example, the National Center for Health Statistics estimates that in 2023, there will be 1,958,310 new cancer cases and 609,820 cancer-related deaths in the U.S., highlighting the urgent need for effective cancer treatment strategies that utilize genomic biomarkers for personalized medicine.
- Recent Developments: In June 2023, Invivoscribe collaborated with Complete Genomics to create and market biomarker tests using next-generation sequencing platforms. These tests aim to improve upfront screening and monitoring for measurable residual disease (MRD), representing a significant advancement in oncology.
Geographical Trends Influencing the Genomic Biomarkers Market:The market is segmented by regions such as North America, South America, Europe, the Middle East and Africa, and Asia Pacific:
- Asia Pacific Growth: Key countries like China, Japan, India, and South Korea are significant contributors in this region. India alone is projected to have 1,461,427 new cancer cases in 2022, with estimates suggesting a cancer burden of 29.8 million by 2025 according to the Indian Council of Medical Research. This dramatic rise is fueling the adoption of genomic biomarkers.
- North America Dominance: North America is expected to maintain a considerable share of the genomic biomarkers market due to leading industry players like MEDiC Life Sciences and Illumina Inc., along with ongoing research efforts in the region.
Overall, the genomic biomarkers market is set for substantial growth driven by the increasing incidence of chronic diseases and advancements in personalized medicine technologies.
Reasons for buying this report:-
- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Report Coverage:
- Historical data & forecasts from 2022 to 2030
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
- Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
The genomic biomarkers market has been segmented as following:
By Type
- Predictive Biomarkers
- Prognostic Biomarkers
By Indication
- Oncology
- Cardiovascular diseases
- Neurological diseases
- Renal Disorders
- Others
By End User
- Hospitals
- Diagnostic Centers
- Others
By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- China
- India
- Japan
- South Korea
- Taiwan
- Thailand
- Indonesia
- Others
TABLE OF CONTENTS
1. INTRODUCTION
- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base and Forecast Years Timeline
- 1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
- 2.1. Research Design
- 2.2. Research Process
- 2.3. Data Validation
3. EXECUTIVE SUMMARY
- 3.1. Key Findings
- 3.2. Analyst View
4. MARKET DYNAMICS
- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Supplier
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
5. GENOMIC BIOMARKERS MARKET BY TYPE
- 5.1. Introduction
- 5.2. Predictive Biomarkers
- 5.3. Prognostic Biomarkers
6. GENOMIC BIOMARKERS MARKET BY INDICATION
- 6.1. Introduction
- 6.2. Oncology
- 6.3. Cardiovascular diseases
- 6.4. Neurological diseases
- 6.5. Renal Disorders
- 6.6. Others
7. GENOMIC BIOMARKERS MARKET BY END USER
- 7.1. Introduction
- 7.2. Hospitals
- 7.3. Diagnostic Centers
- 7.4. Others
8. GENOMIC BIOMARKERS MARKET BY GEOGRAPHY
- 8.1. Global Overview
- 8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
- 8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
- 8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Italy
- 8.4.5. Spain
- 8.4.6. Others
- 8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. United Arab Emirates
- 8.5.3. Others
- 8.6. Asia-Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Taiwan
- 8.6.6. Thailand
- 8.6.7. Indonesia
- 8.6.8. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 9.1. Major Players and Strategy Analysis
- 9.2. Emerging Players and Market Lucrativeness
- 9.3. Mergers, Acquisitions, Agreements, and Collaborations
- 9.4. Competitive Dashboard
10. COMPANY PROFILES
- 10.1. Almac Group
- 10.2. Bio-Rad Laboratories Inc.
- 10.3. Eurofins Scientific
- 10.4. Myriad Genetics Inc
- 10.5. QIAGEN
- 10.6. Thermo Fisher Scientific Inc
- 10.7. Illumina, Inc.
- 10.8. REVEAL GENOMICS, S.L.
- 10.9. Guardant Health
- 10.10. Complete Genomics Incorporated
02-2729-4219
+886-2-2729-4219
基因生物標記市場：按產品類型、適應症和最終用戶分類 - 2025-2030 年全球預測
基因組生物標記市場，按類型、疾病適應症、驗證、最終用戶和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測